Overview

An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is assess whether ambrisentan can help people with exercise- induced pulmonary arterial hypertension (EIPAH). The investigators also want to find out if ambrisentan is safe to take without causing excessive side effects.

Phase:

Phase 4

Details

Lead Sponsor:

Brigham and Women's Hospital

Collaborator:

Gilead Sciences

Treatments:

Ambrisentan